Retatrutide: So Much More Than Weight-Loss Research

Beyond the bathroom scales: what researchers are learning about retatrutide, metabolic health, the liver, kidneys and the increasingly fascinating relationship between incretin signalling and the brain.

Ask someone what retatrutide is being researched for and there is a very good chance the answer will be weight loss. It is understandable why. Retatrutide's clinical development has produced substantial reductions in body weight, and those numbers have understandably dominated headlines, social media and much of the public conversation surrounding the molecule. In the original Phase 2 obesity trial, participants receiving the highest studied dose experienced an average body-weight reduction of 24.2% at 48 weeks. More recently, Eli Lilly has reported positive topline results from its Phase 3 development program, although complete peer-reviewed publication of the Phase 3 evidence continues to develop.

The problem with viewing retatrutide exclusively through the bathroom scales is that body weight is only one measurement of a much larger metabolic system. While the headline numbers tell us how many kilograms somebody has lost, they tell us very little about what is happening underneath. Researchers studying retatrutide have also been measuring changes in liver fat, visceral adipose tissue, insulin sensitivity, blood lipids and markers associated with kidney function. At the same time, research across the wider GLP-1 field is beginning to ask increasingly interesting questions about the relationship between incretin signalling and the brain's reward system. The result is a scientific story that extends considerably further than weight loss alone.

Retatrutide is particularly interesting because it is designed to activate three different receptor systems: GLP-1, GIP and glucagon receptors. GLP-1 and GIP are incretin hormones involved in glucose regulation and metabolic signalling, while glucagon has its own complex role in glucose and energy metabolism. Rather than targeting one pathway, retatrutide allows researchers to investigate what happens when three interconnected signalling systems are influenced simultaneously. That distinction becomes important when we begin looking at some of the changes observed during its clinical development.

Perhaps the most striking example so far comes from the liver.

Metabolic dysfunction-associated steatotic liver disease, or MASLD, involves excessive accumulation of fat within the liver in association with metabolic dysfunction. It has become increasingly common alongside obesity, insulin resistance and type 2 diabetes. A substudy of retatrutide's Phase 2 obesity trial examined 98 participants with MASLD who had at least 10% liver fat at baseline, using MRI to measure changes in liver-fat content.

The results were substantial. After 24 weeks, average relative liver-fat reductions were 42.9% in the 1 mg group, 57.0% in the 4 mg group, 81.4% in the 8 mg group and 82.4% in the 12 mg group, compared with a slight increase of 0.3% with placebo. At 24 weeks, liver-fat content had fallen below 5% in 79% of participants receiving 8 mg and 86% of those receiving 12 mg.

Those numbers are impressive, but they need to be interpreted carefully. It would be very easy to reduce them to a headline claiming that retatrutide simply “removes fat from the liver.” The actual biology is considerably more complicated. Reductions in liver fat were associated with reductions in body weight, waist circumference and abdominal fat, as well as changes in metabolic measurements related to insulin sensitivity and lipid metabolism. Weight loss itself can substantially reduce liver fat, while improvements in insulin sensitivity can change the way nutrients and fatty acids are handled throughout the body. Glucagon-receptor activity may also be relevant to hepatic metabolism. Researchers therefore aren't simply interested in whether liver fat decreased; they are interested in understanding why it decreased and whether those changes eventually translate into meaningful long-term liver outcomes.

That distinction is important because reducing liver fat on an MRI is not the same thing as proving prevention of cirrhosis, liver failure or other major liver outcomes. Biomarkers and imaging findings can provide compelling signals, but clinical research ultimately needs to establish whether those changes improve outcomes that matter to patients. This is one reason retatrutide's liver research continues rather than ending with an impressive MRI result.

The liver findings also revealed another substantial change occurring beneath the bathroom scales: visceral adipose tissue. Visceral fat is stored within the abdominal cavity around internal organs and is metabolically different from the subcutaneous fat sitting directly beneath the skin. Higher amounts of visceral adipose tissue are strongly associated with cardiometabolic disease. In the MASLD substudy, visceral adipose tissue decreased substantially over the study period, with reductions approaching approximately 48% at 48 weeks in some retatrutide groups. Subcutaneous abdominal fat also declined significantly.

This illustrates why simply saying someone “lost 20 kilograms” provides an incomplete picture of metabolic research. Two people can lose the same amount of body weight while experiencing different changes in visceral fat, subcutaneous fat, liver fat, lean mass and metabolic biomarkers. The number on the scales cannot distinguish between any of them.

Researchers also observed changes in several metabolic measurements. Fasting insulin concentrations declined, measures associated with insulin resistance improved, triglycerides fell and changes were observed in hormones associated with adipose tissue and energy balance, including adiponectin and leptin. Within the MASLD substudy, fasting triglycerides were reduced by more than 40% in the higher-dose groups at 48 weeks. Again, none of this means retatrutide should automatically be described as a treatment for every metabolic abnormality associated with obesity. It demonstrates that multiple metabolic systems were changing simultaneously, which is precisely what researchers are trying to understand.

The kidneys provide another interesting example of where the research has begun moving beyond weight loss, although this is an area where the evidence requires particular caution. Claims that retatrutide “repairs” or “protects” the kidneys go substantially beyond what has currently been demonstrated.

A post-hoc analysis examined kidney-related measurements from two Phase 2 retatrutide trials involving 281 participants with type 2 diabetes and 338 participants with overweight or obesity without diabetes. Researchers assessed estimated glomerular filtration rate, or eGFR, as well as urine albumin-to-creatinine ratio, commonly abbreviated UACR. Albumin appearing in the urine can be an important marker of kidney damage, particularly in people with diabetes and chronic kidney disease.

Among participants with type 2 diabetes, the highest retatrutide dose was associated with a 37% reduction in UACR compared with placebo at 36 weeks, while eGFR did not differ significantly from placebo. Among participants with overweight or obesity without diabetes, reductions in UACR of approximately 28% and 31.5% were observed in the 8 mg and 12 mg groups compared with placebo at 48 weeks. Some measures of estimated kidney filtration were also higher than placebo.

These findings are interesting, but they are not proof that retatrutide prevents kidney disease. The analysis was exploratory and post-hoc, most participants did not have substantial established kidney disease, and baseline albuminuria was generally low. The appropriate conclusion is therefore not that retatrutide has been proven to protect the kidneys, but that researchers observed kidney-related signals interesting enough to justify further investigation.

The research becomes even more intriguing when we move away from traditional metabolic measurements and into the brain.

One of the most recognisable experiences reported with GLP-1 receptor agonists is not simply eating less, but thinking about food less. The internet has adopted the term “food noise” to describe persistent thoughts about eating, cravings and the next meal. It isn't a formal medical diagnosis, but it captures an experience that many people understand immediately. As GLP-1 therapies became more widespread, however, researchers and patients began noticing that changes in reward-related behaviour might not necessarily stop with food.

Some people reported less interest in alcohol. Others described changes in smoking or other habitual reward-seeking behaviours. These observations attracted scientific interest because GLP-1 signalling is not confined to the gastrointestinal system and pancreas. GLP-1 receptors are also found within the central nervous system, including regions involved in appetite, motivation and reward. Research has examined interactions between GLP-1 signalling and neural circuitry associated with dopamine and reinforcement, creating a plausible biological reason to investigate whether incretin-based therapies could influence behaviours extending beyond eating.

Preclinical research has repeatedly found that GLP-1 receptor agonism can alter alcohol intake and drug-seeking behaviour in animal models, with research extending across alcohol, nicotine, opioids and psychostimulants. More recently, the field has begun moving into human studies. Early clinical research involving GLP-1-based treatments and alcohol-use disorder has produced encouraging signals, and recent reviews describe addiction medicine as an emerging area of investigation for this drug class.

This is potentially important, but it is also where the distinction between retatrutide and the broader GLP-1 field becomes essential. Most of the addiction research currently being discussed is not research demonstrating that retatrutide treats addiction. It involves other GLP-1 receptor agonists or preclinical models examining the GLP-1 pathway. Retatrutide activates the GLP-1 receptor, so this broader research provides a legitimate scientific reason to ask similar questions about it. Retatrutide, however, also activates GIP and glucagon receptors, and we cannot simply take findings from another molecule, substitute the word “retatrutide” and call the question settled.

At present, retatrutide should not be described as an established treatment for alcohol dependence, nicotine dependence or any other substance-use disorder. The accurate story is that the wider incretin field has uncovered an unexpected and potentially important relationship between metabolic signalling and reward behaviour, and that discovery raises interesting questions for future retatrutide research.

There is also a fascinating flip side to this discussion. If incretin signalling can potentially reduce the motivational pull of food, alcohol or other highly rewarding stimuli, what happens if some individuals feel as though the volume on reward has been turned down too far?

Across online GLP-1 communities, some people describe a feeling of emotional flatness or reduced motivation. Food may no longer seem particularly exciting, but occasionally the description extends further. Activities that previously felt rewarding may seem less interesting. Some people describe themselves as apathetic, while others use the term anhedonia, which refers to a diminished ability to experience pleasure.

This deserves to be discussed, but it also deserves considerably more caution than it often receives online. There is currently no established clinical syndrome called “retatrutide apathy,” and apathy or anhedonia were not identified as characteristic adverse effects in the published Phase 2 retatrutide obesity trial. The most frequently reported adverse effects were gastrointestinal, particularly nausea, diarrhoea, vomiting and constipation, while dose-dependent increases in heart rate were also observed.

That does not mean individual reports of emotional flatness should simply be dismissed. It means anecdotes alone cannot establish why somebody is experiencing them. Reward processing may genuinely be changing in some individuals, but there are several competing explanations. Someone who previously derived a significant amount of daily pleasure from food may notice its absence once food becomes less salient. Dramatically reduced calorie intake can contribute to fatigue and reduced energy. Rapid weight loss produces substantial physiological changes. Gastrointestinal symptoms can make many everyday activities less enjoyable. Expectations can also influence how people interpret changes once they have read that they are supposedly going to experience them.

The broader scientific literature doesn't point uniformly toward GLP-1 signalling producing anhedonia either. A systematic review examining GLP-1 receptor agonists and reward behaviour discussed the possibility that these drugs may normalise aspects of dysfunctional reward processing in some circumstances rather than simply suppressing pleasure across the board. The scientifically responsible answer to the question “Does retatrutide cause apathy?” is therefore not yes, and it isn't necessarily no. We simply do not currently have sufficient evidence to establish that relationship.

Persistent loss of pleasure, substantial mood changes or other concerning psychological symptoms should therefore not simply be written off as evidence that a GLP-1 pathway is “working.” Reward biology is scientifically fascinating, but mental-health symptoms deserve appropriate clinical attention rather than internet speculation.

Taken together, these different areas of research reveal why describing retatrutide simply as a weight-loss molecule misses much of what makes it interesting. Obesity itself does not exist independently of the rest of human physiology. It intersects with insulin resistance, type 2 diabetes, fatty liver disease, abnormal blood lipids, cardiovascular disease, kidney disease, visceral adiposity and complex neurological systems controlling hunger, satiety, motivation and reward. A molecule simultaneously interacting with GLP-1, GIP and glucagon signalling therefore gives researchers an opportunity to observe changes occurring throughout a deeply interconnected metabolic system.

The challenge is determining which effects are directly attributable to retatrutide's pharmacology and which occur because people have lost substantial amounts of weight. Improvements in liver fat, insulin sensitivity and other metabolic measurements can follow weight loss itself. Changes in calorie intake can influence numerous physiological systems. Individual receptor pathways may contribute additional effects. Untangling those relationships requires controlled research rather than simply observing that several things improved simultaneously.

It is equally important to remember where retatrutide currently sits in its development. As of August 2026, retatrutide remains investigational and has not been approved by the TGA or FDA. Eli Lilly has reported positive topline results from several Phase 3 TRIUMPH studies and has stated that regulatory submissions are expected to begin in 2027, but the complete clinical evidence continues to develop.

That means the different subjects discussed here do not all sit at the same level of evidence. The reduction in liver fat has been demonstrated in controlled human retatrutide research. Kidney-related biomarker changes have been observed in exploratory analyses but require further investigation before conclusions about kidney protection can be made. Metabolic changes involving insulin sensitivity, visceral adiposity and blood lipids have been measured in human trials. Research into addiction and reward is increasingly compelling across the broader GLP-1 field, but it should not yet be presented as proof that retatrutide treats addictive disorders. Reports of apathy or emotional flatness are interesting signals from real-world discussion, but they have not established a recognised retatrutide-induced syndrome.

Keeping those distinctions intact does not make the retatrutide story less exciting. It makes it considerably more interesting.

Perhaps the biggest mistake we can make with retatrutide is assuming that weight loss is the mechanism and everything else happening within the body is simply a collection of side effects. It may be more useful to think about the problem from the opposite direction. Retatrutide interacts with several metabolic signalling systems simultaneously, and those systems communicate across the liver, pancreas, adipose tissue, gastrointestinal system, cardiovascular system, kidneys and brain. When that network changes, body weight is simply one of the outcomes that happens to be particularly easy to see.

The bathroom scales give us a number. They cannot tell us what has happened to liver fat or visceral adipose tissue. They cannot measure insulin sensitivity or urinary albumin. They certainly cannot tell us what is happening inside neural circuits involved in hunger, craving, motivation and reward.

Some of these research questions may ultimately prove clinically important. Others may turn out to be secondary consequences of substantial weight loss rather than unique properties of retatrutide itself. Some of today's most exciting hypotheses may simply fail when larger and better-controlled studies put them to the test.

That is exactly what research is supposed to determine.

Retatrutide doesn't need exaggerated claims to be scientifically interesting. The evidence already gives researchers plenty to investigate.

Weight loss is unquestionably part of the retatrutide story.

It just may not be the whole story.

Continue your research here

References & Further Reading

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023.

Sanyal AJ, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037–2048.

Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports. 2025;10:1980–1992.

McIntyre RS, et al. Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review. 2024.

The potential role of GLP-1 receptor agonists in substance use disorders — a systematic review. 2026.

GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence. 2026.

From Satiety to Substance Use: Neural Mechanisms of GLP-1 Signaling in Appetite and Reward. Biological Psychiatry. 2026.

National Institutes of Health. GLP-1 plus therapy can reduce heavy drinking. 2026.

Eli Lilly and Company. What to know about retatrutide. 2026.

Research Disclaimer

This article is provided for educational and research purposes only and does not constitute medical advice or a recommendation for human use. Retatrutide remains an investigational compound and has not been approved by the TGA or FDA. The research discussed above comes from evidence at different stages of development, including controlled retatrutide trials, exploratory analyses, preclinical research and studies involving other GLP-1 receptor agonists. Findings concerning other GLP-1 receptor agonists should not be assumed to apply to retatrutide, and experimental associations should not be interpreted as established therapeutic effects.